Asset Details
Do you wish to reserve the book?
In silico testing to identify compounds that inhibit ClfA and ClfB binding to the host for the formulation of future drugs against Staphylococcus aureus colonization and infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
In silico testing to identify compounds that inhibit ClfA and ClfB binding to the host for the formulation of future drugs against Staphylococcus aureus colonization and infection
Do you wish to request the book?
In silico testing to identify compounds that inhibit ClfA and ClfB binding to the host for the formulation of future drugs against Staphylococcus aureus colonization and infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
In silico testing to identify compounds that inhibit ClfA and ClfB binding to the host for the formulation of future drugs against Staphylococcus aureus colonization and infection
2024
Overview
is a highly resistant pathogen. It has multiple virulence factors, which makes it one of the most pathogenic bacteria for humankind. The vast increase in antibiotic resistance in these bacteria is a warning of existing healthcare policies. Most of the available antibiotics are ineffective due to resistance; this situation requires the development of drugs that target specific proteins and are not susceptible to resistance.
In this study, we identified a compound that acts as an antagonist of ClfA and ClfB by inhibiting their binding to host cells.
The shortlisted compound's binding activity was tested by docking and molecular dynamics during its interaction with proteins. The identified compound has excellent binding energy with both ClfA (-10.11 kcal/mol) and ClfB (-11.11 kcal/mol).
The molecular dynamics of the protein and compound were stable and promising for further
and
tests. The performance of our compound was tested and compared with that of the control molecule allantodapsone, which was reported in a previous study as a pan inhibitor of the clumping factor. An ADMET study of our selected compound revealed its reliable drug likeliness. This compound is an ideal candidate for
studies.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Adhesins, Bacterial - metabolism
/ Anti-Bacterial Agents - chemistry
/ Anti-Bacterial Agents - pharmacology
/ antimicrobial resistance (AMR)
/ Cellular and Infection Microbiology
/ Coagulase - antagonists & inhibitors
/ Humans
/ Ligands
/ molecular docking & molecular dynamics (MD) simulation
/ Molecular Docking Simulation
/ Molecular Dynamics Simulation
/ Proteins
/ Staphylococcal Infections - drug therapy
/ Staphylococcal Infections - microbiology
/ Staphylococcus aureus - drug effects
/ Staphylococcus aureus - metabolism
/ Toxicity
